In relation to DMSO controls, cultured human primary GBM cells (Fig. 3A) and GBM cell lines (Fig. 3B) responded to TMZ treatment with induction of Akirin-2 mRNA expression up to 1.3-fold (P3) or up to 3.4-fold (A172), and with induction of Twist-1 mRNA expression up to 2.4-fold (P1) or up to 5.4-fold (A172), respectively. Here, AKIRIN2 is linked to glioblastoma.